logo
The big idea: should we embrace boredom?

The big idea: should we embrace boredom?

The Guardian15-06-2025
In 2014, a group of researchers from Harvard University and the University of Virginia asked people to sit alone with their thoughts for 15 minutes. The only available diversion was a button that delivered a painful electric shock. Almost half of the participants pressed it. One man pressed the button 190 times – even though he, like everyone else in the study, had earlier indicated that he found the shock unpleasant enough that he would pay to avoid being shocked again. The study's authors concluded that 'people prefer doing to thinking', even if the only thing available to do is painful – perhaps because, if left to their own devices, our minds tend to wander in unwanted directions.
Since the mass adoption of smartphones, most people have been walking around with the psychological equivalent of a shock button in their pocket: a device that can neutralise boredom in an instant, even if it's not all that good for us. We often reach for our phones for something to do during moments of quiet or solitude, or to distract us late at night when anxious thoughts creep in. This isn't always a bad thing – too much rumination is unhealthy – but it's worth reflecting on the fact that avoiding unwanted mind-wandering is easier than it's ever been, and that most people distract themselves in very similar, screen-based ways.
Smartphones have also increased the pressure to use our time productively, to optimise every minute of our lives. If once a harried commuter might have been forced to stare out of the window or read a book on the train to work, now they may try to catch up on their emails to avoid feeling guilty and inefficient. To sit and do nothing is seen as a waste of time. But that ignores the fact that when we're doing nothing we're often thinking quite hard. What happens to all those difficult or untamed half-thoughts that start to form in the milliseconds before we dig into our pockets and pull out our phones again?
Most psychologists studying boredom would agree that, while it can feel unpleasant, it's useful. Like hunger or loneliness, it alerts us to a need, a desire to do something different. According to Erin Westgate, assistant professor of psychology at the University of Florida, we become bored if something fails to absorb our attention, or when we perceive it as meaningless. This is not to say that something needs to be both engaging and meaningful to keep us interested: doing sudoku might be absorbing but relatively meaningless, while reading a Peppa Pig bedtime story for the 500th time is not engaging but may nonetheless feel like a meaningful thing to do. Watching paint dry is both unstimulating and pointless, which is why it isn't a common pastime.
In any case, when boredom strikes it should ideally serve as a prompt to do something more engaging or meaningful. If you don't react appropriately to your boredom, or perhaps if engaging or meaningful things aren't available to you for whatever reason, you may find yourself becoming chronically bored. That is associated with a range of problems, including depression, anxiety, poor life satisfaction, lower academic achievement, substance abuse and excessive risk-taking.
There is evidence to suggest that chronic boredom is becoming more common, and that this uptick has coincided with the rise of smartphones. In a paper published last year, researchers noted that the proportion of students in China and the US who described themselves as bored steadily increased in the years after 2010, during the first decade of smartphone dominance. Why might digital media have this effect? Research has shown that the main reason we pick up our phones or check our socials is to relieve boredom, but that the behaviour actually exacerbates it. One study, for instance, found that people who were bored at work were more likely to use their smartphones – and subsequently feel even more bored.
It may be that checking your phone only addresses part of what you need when you start to feel bored. Digital devices are very good at attracting your attention – in fact, everything you interact with on a screen has been designed to capture, hold and monetise it – but much of what we do online doesn't feel meaningful. It's incredibly easy to plan to look at your phone for just five minutes and resurface two hours later with Mastermind-level knowledge of the latest Blake Lively controversy or your ex's holiday plans. The average American spends more than four hours a day on their smartphone and more than seven hours a day in total online. That adds up to spending 17 years of your adult life browsing the internet. I expect that even the biggest technophiles would agree that this isn't how they want to spend their one precious life.
Phones' efficacy at whisking us into superficial stimulation short-circuits our boredom and allows us to swiftly evade messages that we might need to hear, such as 'Why am I feeling this?' or 'What do I need that I'm not getting?' If we pause and listen, then perhaps we can make a choice rather than being manipulated by software engineers. When boredom strikes, we should resist the urge to assuage it instantly and ask ourselves: are we in search of pure entertainment or something more purposeful, an opportunity to connect with friends or our community or something different, something new? The people who choose to embrace boredom, at least for a while, may paradoxically experience less of it. It could even be the first step towards a life that feels more stimulating overall: meaningful, creative and free.
Bored and Brilliant by Manoush Zomorodi (Pan Macmillan, £14.99)
Digital Minimalism by Cal Newport (Penguin, £10.99)
The Antidote by Oliver Burkeman (Vintage, £10.99)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

Reuters

time26 minutes ago

  • Reuters

Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

July 31 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and stroke in a large, head-to-head study. In the Lilly-funded trial of more than 13,000 patients with type 2 diabetes and high cardiovascular risk, Mounjaro reduced the risk of major adverse heart events by 8% more than Trulicity, the Indianapolis-based drugmaker said. The risk of death from any cause was 16% lower for Mounjaro patients than for those taking Trulicity, though researchers are still studying the data to understand what is behind the difference. Mounjaro is the company's diabetes drug that targets the GLP-1 protein and is also used for weight loss. In the U.S., the obesity version is sold under the brand name Zepbound. Trulicity, which first won U.S. approval in 2014, has been a go-to treatment for preventing heart disease in people with diabetes since the Food and Drug Administration approved it for that use in 2020 following data showing a 12% reduction in heart-related risk. Once Lilly's top seller, Trulicity hit peak sales of $7.4 billion in 2022, aided by the added heart-related approval, according to the company. Mounjaro stole that mantle last year with $11.5 billion in sales, more than double Trulicity's $5.2 billion. Kenneth Custer, president of Lilly's cardiometabolic health division, told Reuters that the new results make Mounjaro an even stronger choice for patients. The new late-stage study, which spanned nearly five years, was the largest and longest trial yet for tirzepatide - the chemical name for Mounjaro - Lilly said. Custer said the company planned to submit its findings to the FDA later this year for an anticipated 2026 expanded approval. The company and Danish rival Novo Nordisk ( opens new tab have been racing for more than two years to prove their competing GLP-1 drugs, already shown to be powerful weight loss agents and diabetes treatments, can also be used to tackle other major diseases and potentially expand insurance coverage. Lilly has a similar study underway testing Zepbound as a treatment for heart disease in obese patients. The FDA approved Novo's rival drug Wegovy to treat heart disease in obese patients in March 2024. Zepbound has already been shown to reduce the risk of hospitalization, death and other adverse outcomes in a smaller study of obese adults with a common type of heart failure, although the FDA has yet to approve the drug for that indication. In diabetes care versus Novo's Ozempic, Mounjaro has captured more than half of the U.S. market share, while Zepbound accounts for just under 60% of its obesity segment in competition with Wegovy, according to IQVIA data shared with Reuters by an analyst. IQVIA did not respond to a request for confirmation. Mounjaro and Trulicity had similar safety profiles, according to the trial results, with most side effects being mild-to-moderate stomach issues that usually resolved after increasing the dose, Lilly said. The GLP-1 drugs are known to cause gastrointestinal issues and more participants stopped taking Mounjaro due to side effects (13.3%) than Trulicity (10.2%).

Never heard of bruxism? You're probably suffering from it
Never heard of bruxism? You're probably suffering from it

Metro

time26 minutes ago

  • Metro

Never heard of bruxism? You're probably suffering from it

'You've worn your molars right down,' said my dentist, matter-of-factly, as she snapped the latex gloves from her hands. 'I can practically hear your jaw clicking.' I did my best not to feel offended. 'Sorry,' I mumbled, rubbing my aching massester muscles. I'm one of the 8 to 10% of the UK population that grinds their teeth in some way — and I'm betting, you are too. I'm not entirely sure when it started, but these days, I'm all-too-aware that I do it pretty much every night. I've woken myself up one-too-many times by accidentally biting down on my tongue (yes, it really hurts) and when my alarm goes off, I open my eyes with an aching jaw. The habit seeps into my waking hours too. I'll suddenly become aware that my jaw is clenched, as though that's its default position. I once heard (e.g. watched a TikTok video) that the three-finger test is a quick way to asses your jaw mobility. If you can fit three stacked fingers between your upper and lower teeth, you're in the normal range. I can only just about do it. But bruxism, the umbrella term for teeth-grinding or jaw clenching, does more than just make your jaw ache. In fact, it can cause a whole host of issues, from dental problems and headaches, to pain in the face, neck or shoulders, and TMJ disorders. To put it mildly, teeth grinding is no picnic — and it's even more annoying when you consider that you're most likely doing it subconciously. And while the current estimates would suggest that around 6.7 million Brits deal with condition, it seems to be on the rise. Post-pandemic, a USA-based 2021 survey among dentists found that 70% reported an increase in patients grinding and clenching their teeth. More recently, the hashtag #teethgrinding on TikTok has a staggering 262.9 million views, while #unclencyourjaw has 37.7 million. You can even buy tshirts and artwork on Etsy emblazoned with the phrase 'unclench your jaw'. And dentist Dr Sahil Patel, of London's Marylebone Smile Clinic, tells Metro that he's seeing an increasing number of patients displaying signs of bruxism. 'Well developed jaw muscles show as a squarer facial appearance or stronger jawline,' he explains. 'And, on the teeth themselves, bruxism causes accelerated tooth wear and breakage, making teeth look shorter, squarer and yellower. Tooth sensitivity and gum recession can also be a sign.' While it's not always clear why people do it, stress and anxiety is a well-observed cause. 'Our patients are absoloutely more stressed than ever,' Dr Sahil says. 'They may not always disclose it to us, but we can sense when someone is stressed. We're seeing it more with younger people.' Mental Health UK's annual Burnout Report, released in January 2025, found that one in three adults either 'always or often' experience high or extreme levels of pressure or stress, while nine in 10 say they've experienced it at some point over the last year. Mind also found that women are more likely than men to experience common mental health problems (20.7% of women compared to 13.2% of men affected), with young women aged 16 to 24 at the highest risk. It's worth nothing that women are also more likely to experience bruxism, particularly when they're awake. Experts are pretty much in agreement that society is increasinly stressful. Chartered psychologist, Dr Manpreet Dhuffar-Pottiwal says we live an era of 'uncertainty and instability'. She tells Metro: 'Political unrest, economic fluctuations, and environmental crises result in an unpredictability which leaves people feeling out of control regarding their futures.' Our 'always-online' culture, particularly experienced by younger generations also doesn't help, as Dr Manpreet says we face 'technological overload.' 'Social media platforms promote curated representations of life, leading us to measure their worth against others. Additionally, urbanisation has contributed to a disconnection from nature. People confined to busy city lives miss out on the calming effects of the natural world.' Workplace pressures have changed too. 'The rise of remote work and gig economies has introduced ambiguity about job security and increased workloads,' says Dr Manpreet. 'Many young employees, striving for stability in uncertain times, experience burnout and chronic stress as they juggle multiple responsibilities. 'Rigid schedules and the lack of work-life balance lead many to neglect self-care practices.' And finally, as ever, the global pandemic plays a part. Dr Manpreet says: 'It heightened health-related anxieties, with individuals increasingly focused on personal safety. 'This ongoing concern can create a cycle of stress that affects various facets of life. 'It's no surprise that there's a growing prevalence of conditions like bruxism.' So, aside from taking an indefinite holiday to escape the stressors of daily life, what can we do to relieve all this tension? According to Dr Sahil, your dentist can help. 'We can't manage your stress, but we can do a few things to manage the symptoms,' he says. 'Night guards can cushion the contact between the teeth during the night, or reainers, which are thinner, are designed to keep the teeth in their position and protect from night grinding. 'They come in many different forms and materials, but the ballpark cost for these is between £250 and £500.' Alternatively, nurse prescriber and aesthetic trainer, Natalja Andrejeva, says that Botox is an 'emerging go-to solution' for teeth-grinding. 'Over the past few years, I've seen a noticeable rise in clicents seeking relief from bruxism using Botox, especially post-pandemic,' she tells Metro. 'Botox is injected into the masseter muscles to relax them. This reduces the intensity of clenching and grinding without affecting your ability to chew or speak.' More Trending The result? 'Less jaw tension, fewer headaches, and better sleep and quality of life. You'll also get a slightly slimmer jawline,' adds Natalja, founder of Face Code Aesthetic, where she offers the treatment, starting at £290. 'Typically, treatment would be required every three to six months, depending on muscle strength and individual response. 'But over time, some clients find they can space out treatments more as the habit and symptoms lessen.' Of course, the ultimate — and almost impossible solution — is to live a stress-free life. But until then, be safe in the knowledge that you're far from the only one — and don't forget to unclench your jaw. Do you have a story to share? Get in touch by emailing MetroLifestyleTeam@ View More » MORE: 'I never exercised – then I became a naked rambler' MORE: What happens to your body in a heatwave after Tampa hits record-breaking 100 degrees? MORE: GP reveals 7 common mistakes people make when stopping weight loss jabs Your free newsletter guide to the best London has on offer, from drinks deals to restaurant reviews.

CVS second-quarter profit beats estimates, helped by medical cost oversight
CVS second-quarter profit beats estimates, helped by medical cost oversight

Reuters

time27 minutes ago

  • Reuters

CVS second-quarter profit beats estimates, helped by medical cost oversight

NEW YORK, July 31 (Reuters) - CVS Health (CVS.N), opens new tab beat Wall Street estimates for second-quarter profit on Thursday, as tight oversight of higher medical costs led to improved performance for its Aetna health insurance business. The company also flagged improved performance in its national pharmacy chain and pharmacy benefit management businesses. CVS reported an adjusted quarterly profit of $1.81 per share, above the average analyst estimate of $1.46 per share, according to LSEG data. For full-year 2025, the insurer raised its profit outlook to $6.30 to $6.40 per share, compared with an average analyst estimate of $6.12 as compiled by LSEG. It attributed the raised forecast to its second-quarter performance. CVS previously had expected full-year earnings per share of $6.00 to $6.20. CVS Health's Aetna insurance business reported a medical loss ratio, or the percentage of premiums spent on medical services, of about 89.9% in the second quarter. Analysts expected a ratio of 91.16%, according to LSEG estimates. It was the third quarter in a row that CVS beat earnings targets as the company works on a turnaround after having missed financial targets repeatedly last year. Those problems had stemmed from an unexpected sharp rise in medical costs in its Medicare Advantage plans for people aged 65 and older or with disabilities, and struggles with its pharmacies. "Nothing is a surprise to us this quarter," said CEO David Joyner in an interview with Reuters. Joyner, who joined the company last October, said the Aetna business experienced higher costs in its Medicare Advantage plans sold through groups such as employers or retiree organizations, but those costs were accurately anticipated. Aetna aims to reprice half of those plans for 2026, he added. CVS plans to close 250 brick-and-mortar pharmacies this year in an effort to cut costs, and the company is reducing its government-sponsored health insurance plans. Rivals including UnitedHealth (UNH.N), opens new tab, Elevance (ELV.N), opens new tab and Centene (CNC.N), opens new tab have detailed higher-than-expected medical costs for the second quarter due to a sicker patient profile and mismatched government payment rates, primarily in Medicaid plans for low-income people. Government payment pressure in Medicare Advantage plans has also squeezed insurer margins this year, with the Centers for Medicare and Medicaid Services changing its calculations of how to reimburse plans for their sickest members. Joyner said CVS's primary care unit for seniors, Oak Street Health, is impacted by these regulatory changes, but the changes are manageable. Revenue for CVS's health services segment, which houses its Caremark pharmacy benefit manager, rose 10.2%, due to a more favorable drug mix and plan renewals from existing clients, the company said. Revenue for the retail-pharmacy and drug-infusion business increased by 12.5% during the second quarter, which Joyner said was aided by increases in prescription volumes filled.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store